Accelerate Diagnostics Inc
NASDAQ:AXDX
NASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)

  • LAST PRICE
    0.8910
  • TODAY'S CHANGE (%)
    0.0108 (1.2270%)
  • Bid / Lots
    0.8503/ 12
  • Ask / Lots
    1.0000/ 1
  • Open / Previous Close
    0.8900 / 0.8802
  • Day Range
    0.8813
    0.9300
  • 52 Week Range
    0.7300
    11.9000
  • Volume
    6,244

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

  • May 8, 2024

      Show headlines and story abstract

    • 4:45PM ET on Wednesday May 08, 2024 by MT Newswires
      Companies Mentioned: AXDX
      04:45 PM EDT, 05/08/2024 (MT Newswires) -- ...

    • 4:43PM ET on Wednesday May 08, 2024 by PR Newswire
      Companies Mentioned: AXDX

      Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced financial preliminary results for the first quarter ended March 31, 2024.

      https://mma.prnewswire.com/media/727214/Accelerate_Diagnostics_Logo.jpg

    • 4:42PM ET on Wednesday May 08, 2024 by Dow Jones
      Companies Mentioned: AXDX

    • 4:42PM ET on Wednesday May 08, 2024 by Dow Jones
      Companies Mentioned: AXDX
      Cost of sales 2,198 1,801 Gross profit 723 1,011 Costs and expenses: Research and development 5,173 6,968 Sales, general and administrative 5,706 10,105 Total costs and expenses 10,879 17,073 Loss from operations (10,156) (16,062) Other income (expense): Interest expense (2,450) (418) Interest expense related party -- (1,013) Loss on fair value instruments (3,951) -- Foreign currency exchange gain 19 233 Interest income 200 420 Other (expense) income, net (627) 45 Total other expense, net (6,809) (733) Net loss before income taxes (16,965) (16,795) Provision for income taxes -- -- Net loss ($16,965) ($16,795) Basic and diluted net loss per share ($0.88) ($1.71) Weighted average shares outstanding 19,216 9,830 Other comprehensive loss: Net loss ($16,965) ($16,795) Net unrealized loss on debt securities available-for-sale -- 24 Foreign currency translation adjustment (6) (255) Comprehensive loss ($16,971) ($17,026) ACCELERATE DIAGNOSTICS, INC. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Unaudited (in thousands) Three Months Ended March 31, March 31, 2024 2023 Cash flows from operating activities: Net loss (16,965) (16,795) Adjustments to reconcile net loss to net cash used in operating activities: Depreciation and amortization 858 802 Provision for bad debts 19 -- Equity-based compensation 1,297 555 Amortization of debt discount and issuance costs 1,596 182 Amortization of debt discount related-party -- 572 Loss on disposal of property and equipment 71 11 Unrealized gain on equity investments (53) (50) Units offering issuance cost 680 -- Loss on fair value adjustments 3,951 -- (Increase) decrease in assets: Contributions to deferred compensation plan (12) -- Accounts receivable 386 (11) Inventory (85) (140) Prepaid expense and other (447) (239) Increase (decrease) in liabilities: Accounts payable 312 (977) Accrued liabilities and other (658) 1,945 Accrued interest 850 235 Accrued interest due to related-party -- 441 Deferred revenue and income (285) (79) Deferred compensation 33 181 Net cash used in operating activities (8,452) (13,367) Cash flows from investing activities: Purchases of equipment (513) (12) Maturities of marketable securities -- 8,221 Net cash (used in) provided by investing activities (513) 8,209 Cash flows from financing activities: Proceeds from issuance of Units to related party 2,050 -- Proceeds from issuance of Units 10,232 -- Units offering issuance cost (764) -- Payments on finance leases (79) (77) Net cash provided by financing activities 11,439 (77) Effect of exchange rate on cash (6) (262) (Decrease) increase in cash and cash equivalents 2,468 (5,497) Cash and cash equivalents, beginning of period 12,138 34,905 Cash and cash equivalents, end of period $14,606 $29,408 ACCELERATE DIAGNOSTICS, INC. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (CONTINUED) Unaudited (in thousands) Three Months Ended March 31, March 31, 2024 2023 Non-cash investing activities: Net transfer of instruments from inventory to property and equipment $127 $71 Non-cash financing activities: Net transfer of instruments from inventory to property and equipment $43 $0 Accrued units offering issuance cost $473 $0 Supplemental cash flow information: Interest paid $10 $0

  • May 2, 2024

Peers Headlines